HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The role of endogenous kallikrein inhibition in perioperative transfusion and adverse outcome in cardiac surgical patients.

AbstractOBJECTIVE:
The goal of this study was to explore the relationship among endogenous plasma kallikrein inhibition (KI), perioperative bleeding, and adverse outcomes in cardiac surgery.
DESIGN:
A prospective, observational study.
SETTING:
University teaching hospitals.
PARTICIPANTS:
Cardiac surgical patients.
INTERVENTIONS:
Endogenous plasma KI levels (%) and kallikrein-like activity (KKA) were measured preoperatively, 30 minutes into cardiopulmonary bypass, and at the end of surgery. Patients were divided into quartiles of preoperative KI. Data including risk factors, blood loss, transfusion requirements, and postoperative outcomes were collected.
MEASUREMENTS AND MAIN RESULTS:
Preoperative endogenous KI ranged from 40% to 175%, where 100% represents the activity of pooled healthy volunteer plasma. The quartiles of KI levels were as follows: quartile 1, KI = 40% to 83.8% (n = 40); quartile 2, KI = 84% to 101.5% (n = 40); quartile 3, KI = 102% to 120% (n = 42); and quartile 4, KI = 121% to 175% (n = 38). The hematocrits on admission to the intensive care unit were as follows: quartile 1, 28% +/- 4%; quartile 2, 26% +/- 4%; quartile 3, 26% +/- 4%; and quartile 4, 24% +/- 4% (p = 0.009). Blood product use was similar among quartiles in the operating room. Quartiles 3 and 4 received more blood (p = 0.003) and platelet (p = 0.04) transfusions than quartiles 1 and 2 in the first 24 hours after surgery. More patients in quartile 4 were ventilated for more than 24 hours after surgery (p < 0.05). Hospital length of stay was longest in quartile 4 (p = 0.002).
CONCLUSION:
Contrary to expectation, higher endogenous KI levels were associated with more blood product transfusion, longer postoperative mechanical ventilation, and hospital length of stay. These findings raise questions as to the role of KI in postoperative outcomes.
AuthorsCatherine M N O'Malley, Robert J Frumento, Ian J Mackie, Michael J Gallimore, Andrew L Hirsh, Elliott Bennett-Guerrero
JournalJournal of cardiothoracic and vascular anesthesia (J Cardiothorac Vasc Anesth) Vol. 21 Issue 1 Pg. 23-7 (Feb 2007) ISSN: 1053-0770 [Print] United States
PMID17289475 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Hemostatics
  • Aprotinin
  • Kallikreins
Topics
  • Aged
  • Aprotinin (administration & dosage)
  • Blood Loss, Surgical (prevention & control, statistics & numerical data)
  • Blood Transfusion (methods)
  • Cardiac Surgical Procedures (methods)
  • Cardiopulmonary Bypass (methods)
  • Cohort Studies
  • Female
  • Hematocrit (methods)
  • Hemostatics (administration & dosage)
  • Humans
  • Intraoperative Complications (prevention & control)
  • Kallikreins (antagonists & inhibitors, blood)
  • Length of Stay
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care (methods)
  • Perioperative Care (methods)
  • Postoperative Complications (prevention & control)
  • Prospective Studies
  • Respiration, Artificial (methods)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: